指南与共识泌尿男性生殖肿瘤

非去势晚期、复发或转移性前列腺癌的初始管理:ASCO指南更新

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update.
指南 / 共识 · J Clin Oncol · 2021-01-26

该ASCO指南更新基于系统文献综述,纳入4部临床实践指南、19篇系统综述、47项III期随机对照试验等证据,针对非去势晚期、复发或转移性前列腺癌的初始激素管理提出推荐。核心推荐包括:ADT联合多西他赛、阿比特龙、恩扎卢胺或阿帕他胺为转移性非去势前列腺癌的四种独立标准治疗;局部晚期非转移性患者放疗后应考虑ADT联合阿比特龙和泼尼松龙而非单用去势治疗。

要点

  • ADT联合多西他赛、阿比特龙、恩扎卢胺或阿帕他胺是转移性非去势前列腺癌的四种独立标准治疗。
  • 放疗后的非去势局部晚期非转移性患者应考虑ADT联合阿比特龙和泼尼松龙,而非单用去势治疗。
  • 高危生化复发非转移性患者可提供间歇性ADT,低危者可提供主动监测。

核心结论

  • ADT联合多西他赛、阿比特龙、恩扎卢胺或阿帕他胺代表转移性非去势前列腺癌的四种独立标准治疗。
  • 目前不推荐这些药物以任何特定组合或序列使用。
  • ADT联合阿比特龙和泼尼松龙应考虑用于放疗后的非去势局部晚期非转移性前列腺癌,而非单用去势治疗。

研究设计与样本

  • 专家小组基于系统文献综述制定推荐,推荐经专家小组和ASCO临床实践指南委员会批准。
  • 证据包括4部临床实践指南、1部指南背书、19篇系统综述(含或不含荟萃分析)、47项III期随机对照试验、9项队列研究和2篇综述文章。

主要发现

  • ADT联合多西他赛、阿比特龙、恩扎卢胺或阿帕他胺应提供给转移性非去势前列腺癌男性,包括接受过先前治疗但尚未进展者。
  • 放疗后的非去势局部晚期非转移性前列腺癌男性应考虑ADT联合阿比特龙和泼尼松龙。
  • 初始表现为非去势局部晚期非转移性且未接受过局部治疗、不愿或不能接受放疗的男性可提供立即ADT。
  • 高危生化复发非转移性前列腺癌男性可提供间歇性ADT,低危者可提供主动监测。
  • 专家小组目前不支持在非去势 setting 中使用微粉化醋酸阿比特龙或250 mg剂量阿比特龙随低脂早餐服用。

关键数值与推荐

  • ADT联合多西他赛、阿比特龙、恩扎卢胺或阿帕他胺为转移性非去势前列腺癌的四种独立标准治疗。
  • 目前不能推荐这些药物以任何特定组合或序列使用。
  • ADT联合阿比特龙和泼尼松龙应考虑用于放疗后的非去势局部晚期非转移性前列腺癌,而非单用去势治疗。
  • 立即ADT可提供给未接受过局部治疗且不愿或不能接受放疗的非去势局部晚期非转移性男性。
  • 间歇性ADT可提供给高危生化复发非转移性前列腺癌男性,主动监测可提供给低危者。

临床怎么用

  • 转移性非去势前列腺癌患者应接受ADT联合多西他赛、阿比特龙、恩扎卢胺或阿帕他胺之一。
  • 放疗后的局部晚期非转移性患者优先考虑ADT联合阿比特龙和泼尼松龙而非单用去势治疗。
  • 根据生化复发风险分层,高危者可选择间歇性ADT,低危者可选择主动监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Update all preceding ASCO guidelines on initial hormonal management of noncastrate advanced, recurrent, or metastatic prostate cancer. METHODS: The Expert Panel based recommendations on a systematic literature review. Recommendations were approved by the Expert Panel and the ASCO Clinical Practice Guidelines Committee. RESULTS: Four clinical practice guidelines, one clinical practice guidelines endorsement, 19 systematic reviews with or without meta-analyses, 47 phase III randomized controlled trials, nine cohort studies, and two review papers informed the guideline update. RECOMMENDATIONS: Docetaxel, abiraterone, enzalutamide, or apalutamide, each when administered with androgen deprivation therapy (ADT), represent four separate standards of care for noncastrate metastatic prostate cancer. Currently, the use of any of these agents in any particular combination or series cannot be recommended. ADT plus docetaxel, abiraterone, enzalutamide, or apalutamide should be offered to men with metastatic noncastrate prostate cancer, including those who received prior therapies, but have not yet progressed. The combination of ADT plus abiraterone and prednisolone should be considered for men with noncastrate locally advanced nonmetastatic prostate cancer who have undergone radiotherapy, rather than castration monotherapy. Immediate ADT may be offered to men who initially present with noncastrate locally advanced nonmetastatic disease who have not undergone previous local treatment and are unwilling or unable to undergo radiotherapy. Intermittent ADT may be offered to men with high-risk biochemically recurrent nonmetastatic prostate cancer. Active surveillance may be offered to men with low-risk biochemically recurrent nonmetastatic prostate cancer. The panel does not support use of either micronized abiraterone acetate or the 250 mg dose of abiraterone with a low-fat breakfast in the noncastrate setting at this time.Additional information is available at www.asco.org/genitourinary-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Virgo KS, Rumble RB, de Wit R, et al. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2021. PMID: 33497248. doi:10.1200/JCO.20.03256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。